Monday, Sep 30, 1996

Genentech Files Amended Complaint Against Novo Nordisk

South San Francisco, Calif. -- September 30, 1996 --

Genentech, Inc. (NYSE: GNE) announced today that it filed an amended complaint in the U.S. District Court for the Southern District of New York alleging that Novo-Nordisk infringes five Genentech patents in the manufacture and sale of Novo's recombinant human insulin product, Novolin., in the United States.

"Novo-Nordisk has already acknowledged in court Genentech's significant contribution to the development of recombinant human insulin," said Stephen Raines, Genentech's Vice President for Intellectual Property. The basic patented inventions on which we have brought suit played a major part in the creation of the biotechnology industry. Novo-Nordisk or any other company should not freely expropriate patented inventions that were created at great risk and cost to Genentech."

Genentech filed an earlier complaint that alleged that Novo-Nordisk's manufacture and sale of its recombinant human growth hormone product, Norditropin., infringed Genentech's patents, and a preliminary injunction was granted by the District Court in New York to prohibit the sale or offer for sale of Norditropin in the United States.

Novo's appeal of that preliminary injunction is pending before the U.S. Court of Appeals for the Federal Circuit.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. The company is headquartered in South San Francisco, California and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.

# # #